International Journal of Cancer Management

Published by: Kowsar

Survival and Recurrence Rate in Patients with Head and Neck Cancer and Associated Prognostic Factors

Elaheh Talebi Ghane 1 , Ahmad Reza Baghestani 2 , * , Farid Zayeri 3 , Ideh Talimkhani 4 and Sahar Masoudi 5
Authors Information
1 Department of Biostatistics, Faculty of Paramedical Sciences, Student’s Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Department of Biostatistics, Physiotherapy Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Department of Biostatistics, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Department of Oral and Maxillofacial Surgery, Faculty of Medical Science, Hamadan University of Medical Science, Hamadan, Iran
5 Department of Biostatistics, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
Article information
  • International Journal of Cancer Management: August 2018, 11 (8); e12794
  • Published Online: August 8, 2018
  • Article Type: Research Article
  • Received: May 8, 2017
  • Revised: April 17, 2018
  • Accepted: April 24, 2018
  • DOI: 10.5812/ijcm.12794

To Cite: Talebi Ghane E, Baghestani A R, Zayeri F, Talimkhani I, Masoudi S. Survival and Recurrence Rate in Patients with Head and Neck Cancer and Associated Prognostic Factors, Int J Cancer Manag. 2018 ; 11(8):e12794. doi: 10.5812/ijcm.12794.

Abstract
Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371(9625):1695-709. doi: 10.1016/s0140-6736(08)60728-x.
  • 2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. doi: 10.1002/ijc.29210. [PubMed: 25220842].
  • 3. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108. doi: 10.3322/caac.21262. [PubMed: 25651787].
  • 4. Ragin CC, Modugno F, Gollin SM. The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res. 2007;86(2):104-14. doi: 10.1177/154405910708600202. [PubMed: 17251508].
  • 5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: Cancer J Clinic. 2015;65(1):5-29. doi: 10.3322/caac.21254.
  • 6. Pruegsanusak K, Peeravut S, Leelamanit V, Sinkijcharoenchai W, Jongsatitpaiboon J, Phungrassami T, et al. Survival and prognostic factors of different sites of head and neck cancer: an analysis from Thailand. Asian Pac J Cancer Prev. 2012;13(3):885-90. [PubMed: 22631666].
  • 7. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937-44. doi: 10.1056/NEJMoa032646. [PubMed: 15128893].
  • 8. Ho AS, Kraus DH, Ganly I, Lee NY, Shah JP, Morris LG. Decision making in the management of recurrent head and neck cancer. Head Neck. 2014;36(1):144-51. doi: 10.1002/hed.23227. [PubMed: 23471843].
  • 9. Lancaster T, Intrator O. Panel data with survival: hospitalization of HIV-positive patients. J American Statistic Associat. 1998;93(441):46-53. doi: 10.1080/01621459.1998.10474086.
  • 10. Liu L, Wolfe RA, Huang X. Shared frailty models for recurrent events and a terminal event. Biometrics. 2004;60(3):747-56. doi: 10.1111/j.0006-341X.2004.00225.x. [PubMed: 15339298].
  • 11. Huang X, Liu L. A joint frailty model for survival and gap times between recurrent events. Biometrics. 2007;63(2):389-97. doi: 10.1111/j.1541-0420.2006.00719.x. [PubMed: 17688491].
  • 12. Rondeau V, Mathoulin-Pelissier S, Jacqmin-Gadda H, Brouste V, Soubeyran P. Joint frailty models for recurring events and death using maximum penalized likelihood estimation: application on cancer events. Biostatistics. 2007;8(4):708-21. doi: 10.1093/biostatistics/kxl043. [PubMed: 17267392].
  • 13. Mazroui Y, Mathoulin-Pelissier S, Soubeyran P, Rondeau V. General joint frailty model for recurrent event data with a dependent terminal event: Application to follicular lymphoma data. Stat Med. 2012;31(11-12):1162-76. doi: 10.1002/sim.4479. [PubMed: 22307954].
  • 14. Tiwana MS, Wu J, Hay J, Wong F, Cheung W, Olson RA. 25 year survival outcomes for squamous cell carcinomas of the head and neck: population-based outcomes from a Canadian province. Oral Oncol. 2014;50(7):651-6. doi: 10.1016/j.oraloncology.2014.03.009. [PubMed: 24731736].
  • 15. Ricketts K, Williams M, Liu ZW, Gibson A. Automated estimation of disease recurrence in head and neck cancer using routine healthcare data. Comput Methods Programs Biomed. 2014;117(3):412-24. doi: 10.1016/j.cmpb.2014.08.008. [PubMed: 25306243].
  • 16. Amar A, Chedid HM, Rapoport A, Dedivitis RA, Cernea CR, Brandao LG. Update of assessment of survival in head and neck cancer after regional recurrence. J Oncol. 2012;2012.
  • 17. Alvarez Marcos CA, Llorente Pendás JL, Franco Gutierrez V, Fernández Espina H, Alonso Guervos M, Suárez Nieto C, et al. Tumour recurrence in squamous head and neck cancer. Acta Otorrinolaringol (English Edition). 2007;58(4):156-63. doi: 10.1016/s2173-5735(07)70324-1.
  • 18. Masoudi S, Montazeri SA, Pourdanesh F, Biglarian A, Kazemi M, Rahgozar M. A new approach to survival analysis of head and neck squamous cell carcinoma. Archiv Iran Med (AIM). 2017;20(8).
  • 19. Kavousi A, Meshkani MR, Mohammadzadeh M. Spatial analysis of relative risk of lip cancer in Iran: a Bayesian approach. Environmetric. 2009;20(4):347-59. doi: 10.1002/env.927.
  • 20. Rad M, Chamani G, Zarei M, Hashemipour M. Epidemiological aspects of head and neck cancers in a group of Iranian population. J Dentistr Shiraz Univ Med Sci. 2010;10:50-6.
  • 21. Larizadeh MH, Damghani MA, Shabani M. Epidemiological characteristics of head and neck cancers in southeast of iran. Iran J Cancer Prev. 2014;7(2):80-6. [PubMed: 25250154]. [PubMed Central: PMC4142945].
  • 22. Mirzaei M, Hosseini SA, Ghoncheh M, Soheilipour F, Soltani S, Soheilipour F, et al. Epidemiology and trend of head and neck cancers in Iran. Glob J Health Sci. 2015;8(1):189-93. doi: 10.5539/gjhs.v8n1p189. [PubMed: 26234980]. [PubMed Central: PMC4803954].
  • 23. Novin K, Ameri A, Faraji S, Torbati P, Mortazavi N. Head and neck squamous cell carcinoma in Iran: clinico-pathological and treatment-related factors influencing survival. Iran J Cancer Preven. 2015;8(5). doi: 10.17795/ijcp-3842.
  • 24. World Health Organization. Head and neck cancer. Union for international cancer control. 2014 review of cancer medicines on the WHO list of essential medicines. 2014. Available from: http://www.who.int/selection_medicines/committees/expert/20/applications/cancer/en/#.
  • 25. Braakhuis BJ, Leemans CR, Visser O. Incidence and survival trends of head and neck squamous cell carcinoma in the Netherlands between 1989 and 2011. Oral Oncol. 2014;50(7):670-5. doi: 10.1016/j.oraloncology.2014.03.008. [PubMed: 24735546].
  • 26. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945-52. doi: 10.1056/NEJMoa032641. [PubMed: 15128894].
  • 27. Sakashita T, Homma A, Hayashi R, Kawabata K, Yoshino K, Iwae S, et al. The role of initial neck dissection for patients with node-positive oropharyngeal squamous cell carcinomas. Oral Oncol. 2014;50(7):657-61. doi: 10.1016/j.oraloncology.2014.03.003. [PubMed: 24726547].
  • 28. Goodwin WJ. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope. 2000;110(3 Pt 2 Suppl 93):1-18. doi: 10.1097/00005537-200003001-00001. [PubMed: 10714711].
  • 29. Kiyota N, Tahara M, Fujii M. Adjuvant treatment for post-operative head and neck squamous cell carcinoma. Jpn J Clin Oncol. 2015;45(1):2-6. doi: 10.1093/jjco/hyu195. [PubMed: 25411434].
  • 30. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27(10):843-50. doi: 10.1002/hed.20279. [PubMed: 16161069].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments